44 results on '"Ginex, Tiziana"'
Search Results
2. Discovery of new antimicrobial thiophene derivatives with activity against drug-resistant Gram negative-bacteria.
- Author
-
Molina-Panadero, Irene, Morales-Tenorio, Marcos, García-Rubia, Alfonso, Ginex, Tiziana, Eskandari, Khalil, Martinez, Ana, Gil, Carmen, and Smani, Younes
- Subjects
ESCHERICHIA coli ,ACINETOBACTER baumannii ,HUMAN fingerprints ,BACTERIAL cell walls ,MOLECULAR docking - Abstract
Our aim is to identify new small molecules with antimicrobial potential, especially against colistin-resistant (Col-R) Acinetobacter baumannii and Escherichia coli. After initial hits identification by fingerprint similarity, MIC of 24 heterocyclic derivatives for A. baumannii and E. coli reference strains, and bactericidal activity of selected thiophenes against Col-R strains were determined. We analyzed changes in bacterial membrane permeability and the OMPs profile. Additionally, we determined bacterial adherence to host cells and performed molecular docking studies to assess their binding to bacterial targets. The compounds’ MICs ranged from 4 to >64 mg/L. Thiophene derivatives 4, 5 and 8 exhibited MIC50 values between 16 and 32 mg/L for Col-R A. baumannii and 8 and 32 mg/L for Col-R E. coli. The time-kill curve assay demonstrated that thiophenes 4 and 8 had bactericidal effects against Col-R A. baumannii and E. coli. Furthermore, treatment with them resulted in increased membrane permeabilization and reduced adherence of these isolates to host cells. Finally, the docking studies showed a stronger binding affinity to CarO1 and Omp33 of A. baumannii and OmpW and OmpC of E. coli. These findings indicate that thiophene derivatives possess antibacterial activity against Col-R A. baumannii and E. coli, suggesting that they may enhance the repertoire of drug treatments against bacteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects
- Author
-
Pont, Caterina, Ginex, Tiziana, Griñán-Ferré, Christian, Scheiner, Matthias, Mattellone, Alexia, Martínez, Noemí, Arce, Elsa M., Soriano-Fernández, Yolanda, Naldi, Marina, De Simone, Angela, Barenys, Marta, Gómez-Catalán, Jesús, Pérez, Belén, Sabate, Raimon, Andrisano, Vincenza, Loza, María Isabel, Brea, José, Bartolini, Manuela, Bolognesi, Maria Laura, Decker, Michael, Pallàs, Mercè, Luque, F. Javier, and Muñoz-Torrero, Diego
- Published
- 2021
- Full Text
- View/download PDF
4. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction
- Author
-
Morales-Tenorio, Marcos, Ginex, Tiziana, Cuesta-Geijo, Miguel Ángel, Campillo, Nuria E., Muñoz-Fontela, César, Alonso, Covadonga, Delgado, Rafael, and Gil, Carmen
- Published
- 2021
- Full Text
- View/download PDF
5. N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction
- Author
-
de Castro, Sonia, Ginex, Tiziana, Vanderlinden, Evelien, Laporte, Manon, Stevaert, Annelies, Cumella, José, Gago, Federico, Camarasa, María José, Luque, F. Javier, Naesens, Lieve, and Velazquez, Sonsoles
- Published
- 2020
- Full Text
- View/download PDF
6. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M
- Author
-
Aragó, Marc, Moreno-Felici, Juan, Abás, Sonia, Rodríguez-Arévalo, Sergio, Hyroššová, Petra, Figueras, Agnes, Viñals, Francesc, Pérez, Belén, Loza, Maria I., Brea, Jose, Latorre, Pedro, Carrodeguas, Jose A., García-Rovés, Pablo M., Galdeano, Carlos, Ginex, Tiziana, Luque, Francisco J., Escolano, Carmen, and Perales, Jose C.
- Published
- 2020
- Full Text
- View/download PDF
7. MBC and ECBL libraries: outstanding tools for drug discovery.
- Author
-
Ginex, Tiziana, Madruga, Enrique, Martinez, Ana, and Gil, Carmen
- Subjects
DRUG discovery ,CHEMICAL libraries ,BIOCHEMISTRY ,PHARMACEUTICAL chemistry ,CHEMICAL biology - Abstract
Chemical libraries have become of utmost importance to boost drug discovery processes. It is widely accepted that the quality of a chemical library depends, among others, on its availability and chemical diversity which help in rising the chances of finding good hits. In this regard, our group has developed a source for useful chemicals named Medicinal and Biological Chemistry (MBC) library. It originates from more than 30 years of experience in drug design and discovery of our research group and has successfully provided effective hits for neurological, neurodegenerative and infectious diseases. Moreover, in the last years, the European research infrastructure for chemical biology EU-OPENSCREEN has generated the European Chemical Biology library (ECBL) to be used as a source of hits for drug discovery. Here we present and discuss the updated version of the MBC library (MBC v.2022), enriched with new scaffolds and containing more than 2,500 compounds together with ECBL that collects about 100,000 small molecules. To properly address the improved potentialities of the new version of our MBC library in drug discovery, up to 44 among physicochemical and pharmaceutical properties have been calculated and compared with those of other well-known publicly available libraries. For comparison, we have used ZINC20, DrugBank, ChEMBL library, ECBL and NuBBE along with an approved drug library. Final results allowed to confirm the competitive chemical space covered by MBC v.2022 and ECBL together with suitable drug-like properties. In all, we can affirm that these two libraries represent an interesting source of new hits for drug discovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Potential of aryl–urea–benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease
- Author
-
Kurt, Belma Zengin, Gazioglu, Isil, Basile, Livia, Sonmez, Fatih, Ginex, Tiziana, Kucukislamoglu, Mustafa, and Guccione, Salvatore
- Published
- 2015
- Full Text
- View/download PDF
9. Screening and Biological Evaluation of Soluble Epoxide Hydrolase Inhibitors: Assessing the Role of Hydrophobicity in the Pharmacophore-Guided Search of Novel Hits.
- Author
-
Vázquez, Javier, Ginex, Tiziana, Herrero, Albert, Morisseau, Christophe, Hammock, Bruce D., and Luque, F. Javier
- Published
- 2023
- Full Text
- View/download PDF
10. N′‑Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile.
- Author
-
Garcia-Rubia, Alfonso, Lasala, Fátima, Ginex, Tiziana, Morales-Tenorio, Marcos, Olal, Catherine, Heung, Michelle, Oquist, Paola, Galindo, Inmaculada, Cuesta-Geijo, Miguel Ángel, Casasnovas, José M., Campillo, Nuria E., Canales, Ángeles, Alonso, Covadonga, Martínez, Ana, Muñoz-Fontela, César, Delgado, Rafael, and Gil, Carmen
- Published
- 2023
- Full Text
- View/download PDF
11. The role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, The IBV-Covid19-Pipeline, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Abstract
Resumen del trabajo presentado a las II Jornadas Científicas PTI + Salud Global, celebradas los días 5 y 6 de octubre de 2022 en el Auditorio Santiago Grisolía de Valencia (España).
- Published
- 2022
12. Inhibition of β‑Amyloid Aggregation in Alzheimer's Disease: The Key Role of (Pro)electrophilic Warheads.
- Author
-
Basagni, Filippo, Naldi, Marina, Ginex, Tiziana, Luque, F. Javier, Fagiani, Francesca, Lanni, Cristina, Iurlo, Matteo, Marcaccio, Massimo, Minarini, Anna, Bartolini, Manuela, and Rosini, Michela
- Published
- 2022
- Full Text
- View/download PDF
13. Application of the quantum mechanical IEF/PCM-MST hydrophobic descriptors to selectivity in ligand binding
- Author
-
Ginex, Tiziana, Muñoz-Muriedas, Jordi, Herrero, Enric, Gibert, Enric, Cozzini, Pietro, and Luque, F. Javier
- Published
- 2016
- Full Text
- View/download PDF
14. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, Ruiz-Rodriguez, Paula, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jeronimo, Rubio, Vicente, and Marina, Alberto
- Subjects
- *
SARS-CoV-2 , *GENETIC mutation , *VACCINE effectiveness , *VIRAL mutation , *VIRAL genomes , *COVID-19 , *AVIAN influenza - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness. Author summary: Since early 2020, the trajectory of the COVID-19 pandemic has mostly been shaped by the appearance of novel variants of the SARS-CoV-2 virus. Accordingly, much of the scientific effort has been directed toward the question of explaining, understanding, and predicting the evolutionary fate of individual mutations in the viral genome. In this article, we focus on A222V, a particular mutation in the Spike protein that emerged in Spain in mid-2020 and reappeared independently in the AY.4.2 subvariant of Delta one year later. As reemerging mutations often indicate an evolutionary advantage, we explored potential mechanisms linking A222V to biologically relevant outcomes. Using serological, functional, structural, and computational approaches, we identified key molecular-level differences conferred by A222V that potentially explain its repeated emergence in different genetic backgrounds. Our results point to subtle changes in the dynamic behavior of the receptor-binding domain in the binding-competent "up" conformation, ones that affect receptor binding itself, but can also act synergistically with other mutations by changing the accessibility of key residues involved in molecular recognition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Azobioisosteres of Curcumin with Pronounced Activity against Amyloid Aggregation, Intracellular Oxidative Stress, and Neuroinflammation.
- Author
-
Hofmann, Julian, Ginex, Tiziana, Espargaró, Alba, Scheiner, Matthias, Gunesch, Sandra, Aragó, Marc, Stigloher, Christian, Sabaté, Raimon, Luque, F. Javier, and Decker, Michael
- Subjects
- *
CURCUMIN , *OXIDATIVE stress , *AMYLOID , *NEUROINFLAMMATION , *NATURAL products , *MICROGLIA - Abstract
Many (poly‐)phenolic natural products, for example, curcumin and taxifolin, have been studied for their activity against specific hallmarks of neurodegeneration, such as amyloid‐β 42 (Aβ42) aggregation and neuroinflammation. Due to their drawbacks, arising from poor pharmacokinetics, rapid metabolism, and even instability in aqueous medium, the biological activity of azobenzene compounds carrying a pharmacophoric catechol group, which have been designed as bioisoteres of curcumin has been examined. Molecular simulations reveal the ability of these compounds to form a hydrophobic cluster with Aβ42, which adopts different folds, affecting the propensity to populate fibril‐like conformations. Furthermore, the curcumin bioisosteres exceeded the parent compound in activity against Aβ42 aggregation inhibition, glutamate‐induced intracellular oxidative stress in HT22 cells, and neuroinflammation in microglial BV‐2 cells. The most active compound prevented apoptosis of HT22 cells at a concentration of 2.5 μm (83 % cell survival), whereas curcumin only showed very low protection at 10 μm (21 % cell survival). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. COVID-19: Drug Targets and Potential Treatments.
- Author
-
Gil, Carmen, Ginex, Tiziana, Maestro, Inés, Nozal, Vanesa, Barrado-Gil, Lucía, Cuesta-Geijo, Miguel Ángel, Urquiza, Jesús, Ramírez, David, Alonso, Covadonga, Campillo, Nuria E., and Martinez, Ana
- Published
- 2020
- Full Text
- View/download PDF
17. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR‑6.
- Author
-
Pérez-Areales, F. Javier, Garrido, María, Aso, Ester, Bartolini, Manuela, De Simone, Angela, Espargaró, Alba, Ginex, Tiziana, Sabate, Raimon, Pérez, Belén, Andrisano, Vincenza, Puigoriol-Illamola, Dolors, Pallàs, Mercè, Luque, F. Javier, Loza, María Isabel, Brea, José, Ferrer, Isidro, Ciruela, Francisco, Messeguer, Angel, and Muñoz-Torrero, Diego
- Published
- 2020
- Full Text
- View/download PDF
18. Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs.
- Author
-
Kang, Dongwei, Feng, Da, Ginex, Tiziana, Zou, Jinmi, Wei, Fenju, Zhao, Tong, Huang, Boshi, Sun, Yanying, Desta, Samuel, De Clercq, Erik, Pannecouque, Christophe, Zhan, Peng, and Liu, Xinyong
- Subjects
PYRIMIDINES ,NON-nucleoside reverse transcriptase inhibitors ,PYRIMIDINE derivatives ,THIOPHENES ,REVERSE transcriptase - Abstract
In this report, a series of novel piperidine-substituted thiophene[3,2- d pyrimidine derivatives were designed to explore the hydrophobic channel of the non-nucleoside reverse transcriptase inhibitors binding pocket (NNIBP) by incorporating an aromatic moiety to the left wing of the lead K-5a2. The newly synthesized compounds were evaluated for anti-HIV potency in MT-4 cells and inhibitory activity to HIV-1 reverse transcriptase (RT). Most of the synthesized compounds exhibited broad-spectrum activity toward wild-type and a wide range of HIV-1 strains carrying single non-nucleoside reverse transcriptase inhibitors (NNRTI)-resistant mutations. Especially, compound 26 exhibited the most potent activity against wild-type and a panel of single mutations (L100I, K103N, Y181C, Y188L and E138K) with an EC 50 ranging from 6.02 to 23.9 nmol/L, which were comparable to those of etravirine (ETR). Moreover, the RT inhibition activity, preliminary structure–activity relationship and molecular docking were also investigated. Furthermore, 26 exhibited favorable pharmacokinetics (PK) profiles and with a bioavailability of 33.8%. Taken together, the results could provide valuable insights for further optimization and compound 26 holds great promise as a potential drug candidate for the treatment of HIV-1 infection. Compound 26 exhibited potent activity against wild-type and a panel of single mutations with an EC 50 ranging from 6.02 to 23.9 nmol/L. Furthermore, 26 exhibited favorable PK profiles and with a bioavailability of 33.8%. These results demonstrated that 26 holds great promise as a potential HIV-1 drug candidate. Image 1 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer-s disease
- Author
-
Kurt, BELMA, Gazioglu, IŞIL, BASILE, Livia, Sonmez, Fatih, GINEX, Tiziana, Kucukislamoglu, Mustafa, GUCCIONE, Salvatore, and GAZİOĞLU, IŞIL
- Subjects
Kurt B., Gazioglu I., BASILE L., Sonmez F., GINEX T., Kucukislamoglu M., GUCCIONE S., -Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer-s disease-, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, cilt.102, ss.80-92, 2015 - Abstract
New benzofuranylthiazole derivatives containing the aryl urea moiety were synthesized and evaluated in vitro as dual acetylcholinesterase (AChE)-butyrylcholinesterase (BuChE) inhibitors. In addition, the cupric reducing antioxidant capacities (CUPRAC) and ABTS cation radical scavenging abilities of the synthesized compounds were assayed. The result showed that all the synthesized compounds exhibited inhibitory activity on both AChE and BuChE with 1-(4-(5-bromobenzofuran-2-yl)thiazol-2-yl)-3-(2fluorophenyl)urea (e25, IC50 value of 3.85 mu M) and 1-(4-iodophenyl)-3-(4-(5-nitrobenzofuran-2-yl) thiazol-2-yl)urea (e38, IC50 value of 2.03 mu M) as the strongest inhibitors against AChE and BuChE, respectively. Compound e38 was 8.5-fold more potent than galanthamine. The selectivity index of e25 and e38 was 2.40 and 0.37 against AChE and BuChE, respectively. Compound e2, e4 and ell (IC50 = 0.2, 0.5 and 1.13 mu M, respectively) showed a better ABTS cation radical scavenging ability than the standard quercetin (IC50 = 1.18 AM). Best poses of compounds e38 on BuChE and e25 on AChE indicate that the thiazole ring and the amidic moiety are important sites of interaction with both ChEs. In addition, the benzofuran ring and phenyl ring are anchored to the side chains of both enzymes by pi-pi(pi-pi) interactions. (C) 2015 Elsevier Masson SAS. All rights reserved.
- Published
- 2015
20. Novel coumarin derivatives as selective acetylcholinesterase inhibitors
- Author
-
Basile, Livia, ZENGİN KURT, BELMA, GAZİOĞLU, IŞIL, Sonmez, Fatih, Küçükislamoğlu, Mustafa, Ginex, Tiziana, Cappello, Valentino, Guccione, Salvatore, and ZENGİN KURT, BELMA
- Subjects
Basile L., ZENGİN KURT B., GAZİOĞLU I., Sonmez F., Küçükislamoğlu M., Ginex T., Cappello V., Guccione S., -Novel coumarin derivatives as selective acetylcholinesterase inhibitors-, XXIII National Meeting on Medicinal Chemistiry, Salerno, İtalya, 06 September 2015, ss.146 - Published
- 2015
21. Lipophilicity in drug design: an overview of lipophilicity descriptors in 3D-QSAR studies.
- Author
-
Ginex, Tiziana, Vazquez, Javier, Gilbert, Enric, Herrero, Enric, and Luque, Francisco J
- Published
- 2019
- Full Text
- View/download PDF
22. Identification of Dihydrofuro[3,4‑d]pyrimidine Derivatives as Novel HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
- Author
-
Kang, Dongwei, Zhang, Heng, Wang, Zhao, Zhao, Tong, Ginex, Tiziana, Luque, Francisco Javier, Yang, Yang, Wu, Gaochan, Feng, Da, Wei, Fenju, Zhang, Jian, De Clercq, Erik, Pannecouque, Christophe, Chen, Chin Ho, Lee, Kuo-Hsiung, Murugan, N. Arul, Steitz, Thomas A., Zhan, Peng, and Liu, Xinyong
- Published
- 2019
- Full Text
- View/download PDF
23. Development and Validation of Molecular Overlays Derived from Three-Dimensional Hydrophobic Similarity with PharmScreen.
- Author
-
Vázquez, Javier, Deplano, Alessandro, Herrero, Albert, Ginex, Tiziana, Gibert, Enric, Rabal, Obdulia, Oyarzabal, Julen, Herrero, Enric, and Luque, F. Javier
- Published
- 2018
- Full Text
- View/download PDF
24. Computational Study of the Aza‐Michael Addition of the Flavonoid (+)‐Taxifolin in the Inhibition of β‐Amyloid Fibril Aggregation.
- Author
-
Ginex, Tiziana, Trius, Marta, and Luque, F. Javier
- Subjects
- *
MICHAEL reaction , *FLAVONOIDS , *AMYLOID beta-protein , *MOLECULAR dynamics , *QUINONE - Abstract
Abstract: Inhibition of abnormal protein self‐aggregation is an attractive strategy against amyloidogenic diseases, but has found limited success due to the complexity of protein self‐assembly, the absence of fully reproducible aggregation assays, and the scarce knowledge of the inhibition mechanisms by small molecules. In this context, catechol‐containing compounds may lead to covalent adducts with amyloid fibrils that interfere with the aggregation process. In particular, the covalent adduct formed between the oxidized form of (+)‐taxifolin and an β‐amyloid (Aβ42) suggests the involvement of a specific recognition motif that enables the chemical reaction with Aβ42. In this study, we have examined the mechanisms implicated in the aza‐Michael addition of the
o ‐quinone species of (+)‐taxifolin with Aβ42 fibrils. The results support the binding of (+)‐taxifolin to the hydrophobic groove delimited by the edges defined by Lys16 and Glu22 residues in the fibril. The chemical reaction proceeds through the nucleophilic attack of the deprotonated amino group of a Lys16 residue in a process activated by the interaction between theo ‐quinone ring with a vicinal Lys16 residue, as well as by a water‐assisted proton transfer, which is the rate‐limiting step of the reaction. This specific inhibition mechanism, which may explain the enhanced anti‐aggregating activity of oxidized flavonoids compared to fresh compounds, holds promise for developing disease‐modifying therapies. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
- Author
-
Leiva, Rosana, Barniol-Xicota, Marta, Codony, Sandra, Ginex, Tiziana, Vanderlinden, Evelien, Montes, Marta, Caffrey, Michael, Luque, F. Javier, Naesens, Lieve, and Vázquez, Santiago
- Published
- 2018
- Full Text
- View/download PDF
26. Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors.
- Author
-
Sonmez, Fatih, Zengin Kurt, Belma, Gazioglu, Isil, Basile, Livia, Dag, Aydan, Cappello, Valentina, Ginex, Tiziana, Kucukislamoglu, Mustafa, and Guccione, Salvatore
- Subjects
ACETAMIDE derivatives ,ACETYLCHOLINESTERASE inhibitors ,CANCER risk factors ,LIVER cancer ,CELL-mediated cytotoxicity ,COUMARIN derivatives - Abstract
New coumaryl-thiazole derivatives with the acetamide moiety as a linker between the alkyl chains and/or the heterocycle nucleus were synthesized andin vitrotested as acetylcholinesterase (AChE) inhibitors. 2-(diethylamino)-N-(4-(2-oxo-2H-chromen-3-yl)thiazol-2-yl)acetamide (6c, IC50value of 43 nM) was the best AChE inhibitor with a selectivity index of 4151.16 over BuChE. Kinetic study of AChE inhibition revealed that6cwas a mixed-type inhibitor. Moreover, the result of H4IIE hepatoma cell toxicity assay for6cshowed negligible cell death. Molecular docking studies were also carried out to clarify the inhibition mode of the more active compounds. Best pose of compound6cis positioned into the active site with the coumarin ring wedged between the residues of the CAS and catalytic triad of AChE. In addition, the coumarin ring is anchored into the gorge of the enzyme by H-bond with Tyr130. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
27. Correction: The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation.
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, Ruiz-Rodriguez, Paula, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jeronimo, Rubio, Vicente, and Marina, Alberto
- Subjects
- *
SARS-CoV-2 , *SUCCESS - Abstract
In the Financial Disclosure, the number for the grant awarded by EPIDNA is incorrect. Reference 1 Ginex T, Marco-Marín C, Wieczór M, Mata CP, Krieger J, Ruiz-Rodriguez P, et al. (2022) The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
28. Development and validation of hydrophobic molecular fields derived from the quantum mechanical IEF/PCM-MST solvation models in 3D-QSAR.
- Author
-
Ginex, Tiziana, Muñoz‐Muriedas, Jordi, Herrero, Enric, Gibert, Enric, Cozzini, Pietro, and Luque, F. J.
- Subjects
- *
HYDROPHOBIC compounds , *QUANTUM mechanics/molecular mechanics , *QSAR models , *SOLVATION , *STRUCTURE-activity relationships , *X-ray crystallography , *GLYCOGEN synthase kinase-3 - Abstract
Since the development of structure-activity relationships about 50 years ago, 3D-QSAR methods belong to the most refined ligand-based in silico techniques for prediction of biological data using physicochemical molecular fields. In this scenario, this study reports the development and validation of quantum mechanical (QM)-based hydrophobic descriptors derived from the parametrized MST continuum solvation model to be used in 3D-QSAR studies within the framework of the Hydrophobic Pharmacophore (HyPhar) method. To this end, five sets of compounds reported in the literature (dopamine D2/D4 antagonists, antifungal 2-aryl-4-chromanones, and inhibitors of GSK-3, cruzain and thermolysin) have been revisited. The results derived from the QM/MST-based hydrophobic descriptors have been compared with previous CoMFA and CoMSIA studies, and examined in light of the available X-ray crystallographic structures of the targets. The analysis reveals that the combination of electrostatic and nonelectrostatic components of the octanol/water partition coefficient yields pharmacophoric models fully comparable with the predictive potential of standard 3D-QSAR techniques. Moreover, the graphical representation of the hydrophobic maps provides a direct linkage with the pattern of interactions found in crystallographic structures. Overall, the introduction of the QM/MST-based descriptors, which could be easily adapted to other continuum solvation formalisms, paves the way to novel computational strategies for disclosing structure-activity relationships in drug design. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. A LIFE-EDESIA project update: An animal-free approach to search for SVHC alternatives
- Author
-
Lorenzetti, Stefano, Benfenati, Emilio, Cozzini, Pietro, Dellafiora, Luca, Fiorino, Ferdinando, Ginex, Tiziana, Giulivo, Monica, La Fauci, Pierpaolo, Basile, Livia, Marcoccia, Daniele, Perissutti, Elisa, Roncaglioni, Alessandra, and Mantovani, Alberto
- Published
- 2015
- Full Text
- View/download PDF
30. FADB: a food additive molecular database for in silico screening in food toxicology.
- Author
-
Ginex, Tiziana, Spyrakis, Francesca, and Cozzini, Pietro
- Subjects
- *
FOOD additives , *DATABASES , *FOOD science , *FOOD industry , *TOXICOLOGY - Abstract
A crucial limit toin silicopreliminary toxicological evaluations in the “food safety” area is the lack of a specific, efficient and available free dataset of 3D small molecules. In this direction, we present the first version of FADB (Food Additives Data Base), a suitable and freely available food additives dataset. FADB is the 3D version of the EAFUS (Everything Added to Food in the United States) list, a sum of WHO, FAO food additive databases and could be a useful starting material in preliminary stages of toxicological assessments. Molecules in FADB are represented through several chemical and 1D identifies, physical properties and 3D (SD and Mol2 file) file formats. FADB also contains important information about functional uses of chemicals as food additives. The aim of the work is to put together substances potentially relevant to food into a “computational” library for virtual screening and docking studies with interesting scenarios for toxicology. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
31. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: the case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczór, Miłosz, Mata, Carlos P., Krieger, James, López-Redondo, Maria Luisa, Francés-Gómez, Clara, Ruiz-Rodriguez, Paula, Melero, Roberto, Sánchez-Sorzano, Carlos Óscar, Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Bravo, Jeronimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscolla, Mireia, Orozco, Modesto, Llácer, José Luis, Carazo, José-Maria, European Commission, Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Comunidad de Madrid, European Research Council, Instituto de Salud Carlos III, Banco Santander, Generalitat Valenciana, Ginex, Tiziana [0000-0002-5739-8713], Marco-Marín, Clara [0000-0002-8813-3515], Wieczor, Milosz [0000-0003-4990-8629], Mata, Carlos P. [0000-0003-3381-7431], Krieger, James [0000-0001-6194-6244], López-Redondo, Marisa [0000-0002-3328-6821], Francés-Gómez, Clara [0000-0001-7341-3824], Ruiz-Rodríguez, Paula [0000-0003-0727-5974], Melero, Roberto [0000-0001-9467-9381], Sorzano, Carlos Óscar S. [0000-0002-9473-283X], Martínez, Marta [0000-0002-8435-5540], Gougeard, Nadine [0000-0001-7338-7267], Forcada-Nadal, Alicia [0000-0003-0179-4044], Zamora-Caballero, Sara [0000-0003-4717-8845], Gozalbo-Rovira, Roberto [0000-0003-3427-3800], Sanz-Frasquet, Carla [0000-0002-6990-3131], Bravo, Jerónimo [0000-0001-6695-2846], Rubio, Vicente [0000-0001-8124-1196], Marina, Alberto [0000-0002-1334-5273], Geller, Ron [0000-0002-7612-4611], Comas, Iñaki [0000-0001-5504-9408], Gil, Carmen [0000-0002-3882-6081], Coscollá, Mireia [0000-0003-0752-0538], Orozco, Modesto [0000-0002-8608-3278], Llácer, José Luis [0000-0001-5304-1795], Carazo, José M. [0000-0003-0788-8447], Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, López-Redondo, Marisa, Francés-Gómez, Clara, Ruiz-Rodríguez, Paula, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Subjects
0303 health sciences ,03 medical and health sciences ,010402 general chemistry ,01 natural sciences ,3. Good health ,030304 developmental biology ,0104 chemical sciences - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has now reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., This research work was supported by the European Commission–NextGenerationEU through the CSIC Global Health Platform. Additionally, authors would like to acknowledge economic support from the Spanish Ministry of Science and Innovation through Grants: PID2019-104757RB-I00 funded by MCIN/AEI/ 10.13039/501100011033, RTI2018-094399-A-I00, and “ERDF A way of making Europe”, by the “European Union”, Grant SEV 2017-0712 funded by MCIN/AEI /10.13039/501100011033, the “Comunidad Autónoma de Madrid" through Grant: S2017/BMD3817, and the European Union (EU) and Horizon 2020 through grants: Marie-Curie Fellowship EnLaCES (MSCA IF 2020, Proposal: 101024130) (to JK), HighResCells (ERC - 2018 - SyG, Proposal: 810057), and iNEXT-Discovery (Proposal: 871037). AM, VR, JB and JLL are funded by CIBERER-ISCIII (proposal: COV20/00437), Fondo Supera COVID-19 (proposal: CSICCOVID19-082), Banco Santander (Proposal: BlockAce), and CSIC PTI Salud Global (Proposal: 202080E110). VR is funded by the Spanish Ministry of Science and Innovation through Grant PID2020-120322RB-C21. IC is funded by project PID2019-104477RB-100, Fondo COVID COV20/00140 and ERC CoG 101001038. MC is funded by the RyC program from the Spanish Ministry of Science and Innovation, the Generalitat Valenciana (SEJI/2019/011).
- Full Text
- View/download PDF
32. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.
- Author
-
Ginex, Tiziana, Garaigorta, Urtzi, Ramírez, David, Castro, Victoria, Nozal, Vanesa, Maestro, Inés, García-Cárceles, Javier, Campillo, Nuria E., Martinez, Ana, Gastaminza, Pablo, and Gil, Carmen
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *ANTIVIRAL agents , *COVID-19 pandemic , *COVID-19 treatment , *SEARCH engines - Abstract
The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. To this end a multi-target virtual screening approach focused on host-based targets related to viral entry, followed by the experimental evaluation of the antiviral activity of selected compounds, has been carried out. As a result, five different potentially repurposable drugs interfering with viral entry—cepharantine, clofazimine, metergoline, imatinib and efloxate—have been identified. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation
- Author
-
Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, The IBV-Covid19-Pipeline, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, Carazo, José M., European Commission, Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia e Innovación (España), Generalitat Valenciana, Comunidad de Madrid, Banco Santander, Instituto de Salud Carlos III, Ginex, Tiziana [0000-0002-5739-8713], Marco-Marín, Clara [0000-0002-8813-3515], Wieczor, Milosz [0000-0003-4990-8629], Mata, Carlos P. [0000-0003-3381-7431], Krieger, James [0000-0001-6194-6244], Ruiz-Rodríguez, Paula [0000-0003-0727-5974], López-Redondo, Marisa [0000-0002-3328-6821], Francés-Gómez, Clara [0000-0001-7341-3824], Melero, Roberto [0000-0001-9467-9381], Sorzano, Carlos Óscar S. [0000-0002-9473-283X], Martínez, Marta [0000-0002-8435-5540], Gougeard, Nadine [0000-0001-7338-7267], Forcada-Nadal, Alicia [0000-0003-0179-4044], Zamora-Caballero, Sara [0000-0003-4717-8845], Gozalbo-Rovira, Roberto [0000-0003-3427-3800], Sanz-Frasquet, Carla [0000-0002-6990-3131], Arranz, Rocío [0000-0001-5321-0915], Bravo, Jerónimo [0000-0001-6695-2846], Rubio, Vicente [0000-0001-8124-1196], Marina, Alberto [0000-0002-1334-5273], Geller, Ron [0000-0002-7612-4611], Comas, Iñaki [0000-0001-5504-9408], Gil, Carmen [0000-0002-3882-6081], Coscollá, Mireia [0000-0003-0752-0538], Orozco, Modesto [0000-0002-8608-3278], Llácer, José Luis [0000-0001-5304-1795], Carazo, José M. [0000-0003-0788-8447], Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Ginex, Tiziana, Marco-Marín, Clara, Wieczor, Milosz, Mata, Carlos P., Krieger, James, Ruiz-Rodríguez, Paula, López-Redondo, Marisa, Francés-Gómez, Clara, Melero, Roberto, Sorzano, Carlos Óscar S., Martínez, Marta, Gougeard, Nadine, Forcada-Nadal, Alicia, Zamora-Caballero, Sara, Gozalbo-Rovira, Roberto, Sanz-Frasquet, Carla, Arranz, Rocío, Bravo, Jerónimo, Rubio, Vicente, Marina, Alberto, Geller, Ron, Comas, Iñaki, Gil, Carmen, Coscollá, Mireia, Orozco, Modesto, Llácer, José Luis, and Carazo, José M.
- Subjects
Vaccines ,SARS-CoV-2 ,Mutació (Biologia) ,Immunology ,COVID-19 ,Peptidyl-Dipeptidase A ,Mutation (Biology) ,Vacunes ,Infections ,Microbiology ,Infeccions ,Virology ,Mutation ,Spike Glycoprotein, Coronavirus ,Genetics ,Humans ,Receptors, Virus ,Parasitology ,Angiotensin-Converting Enzyme 2 ,Genetic Background ,Molecular Biology ,Protein Binding - Abstract
The S:A222V point mutation, within the G clade, was characteristic of the 20E (EU1) SARS-CoV-2 variant identified in Spain in early summer 2020. This mutation has since reappeared in the Delta subvariant AY.4.2, raising questions about its specific effect on viral infection. We report combined serological, functional, structural and computational studies characterizing the impact of this mutation. Our results reveal that S:A222V promotes an increased RBD opening and slightly increases ACE2 binding as compared to the parent S:D614G clade. Finally, S:A222V does not reduce sera neutralization capacity, suggesting it does not affect vaccine effectiveness., In this research work, PRR and TG were supported by salaries from the European Commission–NextGenerationEU through the CSIC Global Health Platform established by EU Council Regulation 2020/2094. The authors would like to acknowledge economic support from: (a) the Spanish Ministry of Science and Innovation through grants: SEV-2017-0712 funded by MCIN/AEI/10.13039/501100011033 (CPM, JK, RM, COSS, MM, RA, JMC); 116880GB-I00 (JLL) and 120322RB-C21 (VR) funded within PID 2020; PID2019-104757RB-I00 funded by MCIN/AEI/10.13039/501100011033/ and “ERDF A way of making Europe”, by the “European Union” (JMC, COSS, RM, MM, CPM) and 104477RB-100 (IC) funded within PID 2019; RYC-2015-18213 (salary of MC) and RYC-2015-17517 (salary of RG) funded by the Ramon y Cajal fellowship program; RTI2018-094399-A-I00 (JMC, COSS, RM, CPM, MC) funded within the Retos Investigación program; the CRIOMECORR project funded as ESFRI-2019-01-CSIC-16; (b) the Horizon 2020 program through Marie Skłodowska-Curie Individual Fellowships EnLaCES (Proposal 101024130, salary of JK) and EPIDNA (Grant ID: 894498, salary of MW); (c) the European Research Council (ERC) through grants: ERC-2018-SyG-810057 HighResCells funded within the EXCELLENT SCIENCE program (JMC, MM, COSS, salary of RM), Grant 871037 iNEXT DISCOVERY (JMC, MM, COSS) and grant CoG-101001038 funded within the Consolidator Grants program (IC); (d) Generalitat Valenciana through grants: SEJI/2019/011 (MC) and SEJI/2019/030 (JLL); (e) Comunidad de Madrid through grant: S2017/BMD-3817 (JMC); (f) Santander Bank through grant: CSIC-COVID19-082 (AM, VR, JB, JLL, RG) funded through the Fondo Supera Covid-19; (g) Instituto de Salud Carlos III through grants: COV20/00437 (AM, VR, JB, JLL) and COV20/00140 (IC), both funded through the Fondos Covid-19 initiative; (h) Spanish National Research Council through grant: 202080E110 funded within the PTI Salud Global initiative (AM, VR, JB, JLL, RG).
- Full Text
- View/download PDF
34. Cover Feature: Computational Study of the Aza‐Michael Addition of the Flavonoid (+)‐Taxifolin in the Inhibition of β‐Amyloid Fibril Aggregation (Chem. Eur. J. 22/2018).
- Author
-
Ginex, Tiziana, Trius, Marta, and Luque, F. Javier
- Subjects
- *
MICHAEL reaction , *FLAVONOIDS , *AMYLOID beta-protein - Published
- 2018
- Full Text
- View/download PDF
35. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
- Author
-
Urtzi Garaigorta, Javier García-Cárceles, Tiziana Ginex, Pablo Gastaminza, Victoria Castro, Vanesa Nozal, David Ramírez, Nuria E. Campillo, Ana Martínez, Inés Maestro, Carmen Gil, Consejo Superior de Investigaciones Científicas (España), European Commission, Fondo Nacional de Desarrollo Científico y Tecnológico (Chile), Comisión Nacional de Investigación Científica y Tecnológica (Chile), Agencia Nacional de Investigación y Desarrollo (Chile), Ministerio de Educación, Cultura y Deporte (España), Ginex, Tiziana [0000-0002-5739-8713], Garaigorta, Urtzi [0000-0002-0683-5725], Ramírez, David [0000-0003-0002-1189], Castro, Victoria [0000-0001-9151-5138], Nozal, Vanesa [0000-0001-5260-5683], Maestro, Inés [0000-0002-5026-5803], Garcia-Carceles, Javier [0000-0003-4614-9639], Martínez, Ana [0000-0002-2707-8110], Gil, Carmen [0000-0002-3882-6081], Ginex, Tiziana, Garaigorta, Urtzi, Ramírez, David, Castro, Victoria, Nozal, Vanesa, Maestro, Inés, Garcia-Carceles, Javier, Martínez, Ana, and Gil, Carmen
- Subjects
Virtual screening ,Coronavirus disease 2019 (COVID-19) ,In silico ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Drug repurposing ,lcsh:Medicine ,lcsh:RS1-441 ,Pharmaceutical Science ,Computational biology ,Article ,lcsh:Pharmacy and materia medica ,Clofazimine ,03 medical and health sciences ,Viral entry ,Drug Discovery ,Pandemic ,Screening method ,Medicine ,030304 developmental biology ,0303 health sciences ,030306 microbiology ,business.industry ,lcsh:R ,COVID-19 ,virtual screening ,35 virtual screening ,Host-based targets ,3. Good health ,Drug repositioning ,Molecular Medicine ,business ,Entry inhibitors ,SARS-CoV-2 evaluation ,medicine.drug - Abstract
The unprecedent situation generated by the COVID-19 global emergency has prompted us to actively work to fight against this pandemic by searching for repurposable agents among FDA approved drugs to shed light into immediate opportunities for the treatment of COVID-19 patients. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. To this end a multi-target virtual screening approach focused on host-based targets related to viral entry, followed by the experimental evaluation of the antiviral activity of selected compounds, has been carried out. As a result, five different potentially repurposable drugs interfering with viral entry—cepharantine, clofazimine, metergoline, imatinib and efloxate—have been identified, This research was funded by CSIC (201980E024, 202020E103 and PIE-RD-COVID-19 ref. E202020E079), EVA (European Virus Archive; grant agreement No 871029), ANID (Agencia Nacional de Investigación y Desarrollo de Chile, grant No COVID0199), and CONICYT-PCI (Comisión Nacional de Investigación Científica y Tecnológica de Chile—Programa de Cooperación Internacional, grant No REDES190074). I.M. was funded by H2020-MSCA-ITN-2017 (grant no. 765912) and V.N. holds a pre-doctoral FPU grant (FPU16/04466)
- Published
- 2020
36. Searching for effective antiviral small molecules against influenza A virus: A patent review
- Author
-
F. Javier Luque, Tiziana Ginex, Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, Ginex, Tiziana, Luque, Francisco Javier, Ginex, Tiziana [0000-0002-5739-8713], and Luque, Francisco Javier [0000-0002-8049-3567]
- Subjects
Hemagglutinin (influenza) ,Neuraminidase ,Context (language use) ,medicine.disease_cause ,Antiviral Agents ,01 natural sciences ,Virus ,Patents as Topic ,Small Molecule Libraries ,M2 proton channel ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,RNA polymerase ,Influenza, Human ,Drug Discovery ,Influenza A virus ,medicine ,Humans ,Hemagglutinin ,Pharmacology ,biology ,Drug discovery ,General Medicine ,Antivirals ,Virology ,Influenza ,COVID-19 Drug Treatment ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Druggable targets ,chemistry ,030220 oncology & carcinogenesis ,biology.protein - Abstract
41 p.-6 fig., Introduction Despite the current interest caused by SARS-Cov-2, influenza continues to be one of the most serious health concerns, with an estimated 1 billion cases of influenza across the globe, including 3-5 million severe cases and 290,000-650,000 deaths worldwide., Areas covered This manuscript reviews the efforts made in the development of small molecules for the treatment of influenza virus, primarily focused on patent applications in the last five years. Attention is paid to compounds targeting key functional viral proteins, such as the M2 channel, neuraminidase, and hemagglutinin, highlighting the evolution toward novel ligands and scaffolds motivated by the emergence of resistant strains. Finally, the discovery of compounds against novel viral targets, such as the RNA-dependent RNA polymerase, is discussed., Expert opinion The therapeutic potential of antiviral agents is limited by the increasing presence of resistant strains. This should encourage research on novel strategies for therapeutic intervention. In this context, the discovery of arbidol and JNJ7918 against hemagglutinin, and current efforts on RNA-dependent RNA polymerase have disclosed novel opportunities for therapeutic treatment. Future studies should attempt to expand the therapeutic arsenal of anti-flu agents, often in combined therapies, which might be relevant to prevent future health challenges caused by influenza virus., This work was supported by the Spanish Ministerio de Economia y Competitividad (MINECO, SAF2017-88107-R; MDM2017-0767; AEI/FEDER UE), and the Generalitat de Catalunya (2017SGR1746)
- Published
- 2020
- Full Text
- View/download PDF
37. N′-phenylacetohydrazide derivatives as potent Ebola virus entry inhibitors with an improved pharmacokinetic profile
- Author
-
Alfonso Garcia-Rubia, Fátima Lasala, Tiziana Ginex, Marcos Morales-Tenorio, Catherine Olal, Michelle Heung, Paola Oquist, Inmaculada Galindo, Miguel Ángel Cuesta-Geijo, José M. Casasnovas, Nuria E. Campillo, Ángeles Canales, Covadonga Alonso, Ana Martínez, César Muñoz-Fontela, Rafael Delgado, Carmen Gil, Fundación 'la Caixa', Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, European Commission, Consejo Superior de Investigaciones Científicas (España), Ministerio de Ciencia e Innovación (España), García-Rubia, Alfonso, Lasala, Fátima, Ginex, Tiziana, Morales-Tenorio, Marcos, Oquist Phillips, Mayra Paola, Galindo, Inmaculada, Cuesta-Geijo,Miguel Angel, Casasnovas, José María, Campillo, Nuria E., Canales, Ángeles, Alonso, Covadonga, Martínez, Ana, Muñoz-Fontela, César, Delgado, Rafael, and Gil, Carmen
- Subjects
Drug Discovery ,Molecular Medicine - Abstract
19 p.-6 fig.-7 tab.-1 graph. abst., Ebola virus (EBOV) is a single-strand RNA virus belonging to the Filoviridae family, which has been associated to most Ebola virus disease outbreaks to date, including the West African and the North Kivu epidemics between 2013 and 2022. This unprecedented health emergency prompted the search for effective medical countermeasures. Following up on the carbazole hit identified in our previous studies, we synthetized a new series of compounds, which demonstrated to prevent EBOV infection in cells by acting as virus entry inhibitors. The in vitro inhibitory activity was evaluated through the screening against surrogate models based on viral pseudotypes and further confirmed using replicative EBOV. Docking and molecular dynamics simulations joined to saturation transfer difference–nuclear magnetic resonance (STD–NMR) and mutagenesis experiments to elucidate the biological target of the most potent compounds. Finally, in vitro metabolic stability and in vivo pharmacokinetic studies were performed to confirm their therapeutic potential., The project leading to these results has received funding from “la Caixa” Foundation under the project code LCF/PR/HR19/52160012. This research was partially supported through ERA-NET-2021-862605. Cofounded by AEI, Spain (PCI2021-121939 (C.A.), PID2019-105237GB-I00 (A.C.), PID2021-122825OB (C.A.), and PID2021-122223OB-I00 (C.G.)), Instituto de Salud Carlos III (CIBERINFEC and FIS PI2100989), and the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2 ID: 101046084). This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). M.M.-T holds a predoctoral FPU grant (FPU18/03493) from MICINN
- Published
- 2023
38. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6
- Author
-
Vincenza Andrisano, Alba Espargaró, Angel Messeguer, Angela De Simone, F. Javier Luque, José Brea, Diego Muñoz-Torrero, Maria Del Mar Capeans Garrido, Francisco Ciruela, Dolors Puigoriol-Illamola, Raimon Sabaté, Tiziana Ginex, Isidre Ferrer, Ester Aso, F. Javier Pérez-Areales, Mercè Pallàs, María Isabel Loza, Manuela Bartolini, Belén Pérez, Pérez-Areales, F Javier, Garrido, María, Aso, Ester, Bartolini, Manuela, De Simone, Angela, Espargaró, Alba, Ginex, Tiziana, Sabate, Raimon, Pérez, Belén, Andrisano, Vincenza, Puigoriol-Illamola, Dolor, Pallàs, Mercè, Luque, F Javier, Loza, María Isabel, Brea, José, Ferrer, Isidro, Ciruela, Francisco, Messeguer, Angel, and Muñoz-Torrero, Diego
- Subjects
GPX1 ,HMOX1 ,Protein Conformation ,SOD2 ,Peptides and proteins ,Pharmacology ,Molecular Dynamics Simulation ,medicine.disease_cause ,01 natural sciences ,Presenilin ,Antioxidants ,Permeability ,Superoxide dismutase ,03 medical and health sciences ,Mice ,Alzheimer Disease ,mental disorders ,Drug Discovery ,Amyloid precursor protein ,medicine ,Animals ,Humans ,Benzopyrans ,Molecular Targeted Therapy ,Inhibition ,030304 developmental biology ,0303 health sciences ,biology ,Animal ,Inhibitors ,Chemistry ,Brain ,Oxidative Stre ,Amides ,Benzopyran ,0104 chemical sciences ,Heme oxygenase ,010404 medicinal & biomolecular chemistry ,Oxidative Stress ,biology.protein ,Molecular Medicine ,Antioxidant ,Oxidative stress ,Human - Abstract
Oxidative stress is a major pathogenic factor in Alzheimer’s disease, but it should not be tackled alone rather together with other key targets to derive effective treatments. The combination of the scaffold of the polar antioxidant lead 7-methoxy-2,2-dimethylchroman-6-ol (CR-6) with that of the lipophilic cholinesterase inhibitor 6-chlorotacrine results in compounds with favorable brain permeability and multiple activities in vitro (acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE-1), and Aβ42 and tau aggregation inhibition). In in vivo studies on wild-type and APP/presenilin 1 (PS1) mice, two selected compounds were well tolerated and led to positive trends, albeit statistically nonsignificant in some cases, on memory performance, amyloid pathology (reduced amyloid burden and potentiated non-amyloidogenic APP processing), and oxidative stress (reduced cortical oxidized proteins and increased antioxidant enzymes superoxide dismutase 2 (SOD2), catalase, glutathione peroxidase 1 (GPX1), and heme oxygenase 1 (Hmox1) and transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2)). These compounds emerge as interesting brain-permeable multitarget compounds, with a potential as anti-Alzheimer agents beyond that of the original lead CR-6., This work was supported by Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and FEDER (SAF2017-82771-R, MDM-2017-0767) and Generalitat de Catalunya (GC) (2017SGR106, 2017SGR1746). Fellowships from GC to F.J.P.-A. and from MCIU to D.P.-I. are gratefully acknowledged.
- Published
- 2020
39. Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
- Author
-
Huang B, Ginex T, Luque FJ, Jiang X, Gao P, Zhang J, Kang D, Daelemans D, De Clercq E, Pannecouque C, Zhan P, and Liu X
- Subjects
- Anti-HIV Agents chemical synthesis, Anti-HIV Agents metabolism, Cell Line, Drug Design, HIV Reverse Transcriptase chemistry, HIV Reverse Transcriptase genetics, HIV Reverse Transcriptase metabolism, Heterocyclic Compounds, 2-Ring chemical synthesis, Heterocyclic Compounds, 2-Ring metabolism, Humans, Microsomes, Liver metabolism, Molecular Dynamics Simulation, Molecular Structure, Mutation, Protein Binding, Pyridines chemical synthesis, Pyridines metabolism, Reverse Transcriptase Inhibitors chemical synthesis, Reverse Transcriptase Inhibitors metabolism, Reverse Transcriptase Inhibitors pharmacology, Structure-Activity Relationship, Anti-HIV Agents pharmacology, HIV-1 drug effects, Heterocyclic Compounds, 2-Ring pharmacology, Pyridines pharmacology
- Abstract
Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6 , 14 , 15 , 21 , 30 , and 33 , were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure-activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure-metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6 , 15 , 21 , and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.
- Published
- 2021
- Full Text
- View/download PDF
40. Searching for effective antiviral small molecules against influenza A virus: A patent review.
- Author
-
Ginex T and Luque FJ
- Subjects
- Drug Discovery, Humans, Influenza, Human virology, Patents as Topic, Small Molecule Libraries, COVID-19 Drug Treatment, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Influenza A virus drug effects, Influenza, Human drug therapy
- Abstract
Introduction: Despite the current interest caused by SARS-Cov-2, influenza continues to be one of the most serious health concerns, with an estimated 1 billion cases across the globe, including 3-5 million severe cases and 290,000-650,000 deaths worldwide. Areas covered: This manuscript reviews the efforts made in the development of small molecules for the treatment of influenza virus, primarily focused on patent applications in the last 5 years. Attention is paid to compounds targeting key functional viral proteins, such as the M2 channel, neuraminidase, and hemagglutinin, highlighting the evolution toward new ligands and scaffolds motivated by the emergence of resistant strains. Finally, the discovery of compounds against novel viral targets, such as the RNA-dependent RNA polymerase, is discussed. Expert opinion: The therapeutic potential of antiviral agents is limited by the increasing presence of resistant strains. This should encourage research on novel strategies for therapeutic intervention. In this context, the discovery of arbidol and JNJ7918 against hemagglutinin, and current efforts on RNA-dependent RNA polymerase have disclosed novel opportunities for therapeutic treatment. Studies should attempt to expand the therapeutic arsenal of anti-flu agents, often in combined therapies, to prevent future health challenges caused by influenza virus. Abbreviations: AlphaLISA: amplified luminescent proximity homogeneous assay; HA: hemagglutinin; NA: neuraminidase; RBD: receptor binding domain; RdRp: RNA-dependent RNA polymerase; SA: sialic Acid; TBHQ: tert-butyl hydroquinone; TEVC: two-electrode voltage clamp.
- Published
- 2021
- Full Text
- View/download PDF
41. Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2- d ]pyrimidine derivatives as potent HIV-1 NNRTIs.
- Author
-
Kang D, Feng D, Ginex T, Zou J, Wei F, Zhao T, Huang B, Sun Y, Desta S, De Clercq E, Pannecouque C, Zhan P, and Liu X
- Abstract
In this report, a series of novel piperidine-substituted thiophene[3,2- d ]pyrimidine derivatives were designed to explore the hydrophobic channel of the non-nucleoside reverse transcriptase inhibitors binding pocket (NNIBP) by incorporating an aromatic moiety to the left wing of the lead K-5a2 . The newly synthesized compounds were evaluated for anti-HIV potency in MT-4 cells and inhibitory activity to HIV-1 reverse transcriptase (RT). Most of the synthesized compounds exhibited broad-spectrum activity toward wild-type and a wide range of HIV-1 strains carrying single non-nucleoside reverse transcriptase inhibitors (NNRTI)-resistant mutations. Especially, compound 26 exhibited the most potent activity against wild-type and a panel of single mutations (L100I, K103N, Y181C, Y188L and E138K) with an EC
50 ranging from 6.02 to 23.9 nmol/L, which were comparable to those of etravirine (ETR). Moreover, the RT inhibition activity, preliminary structure-activity relationship and molecular docking were also investigated. Furthermore, 26 exhibited favorable pharmacokinetics (PK) profiles and with a bioavailability of 33.8%. Taken together, the results could provide valuable insights for further optimization and compound 26 holds great promise as a potential drug candidate for the treatment of HIV-1 infection., (© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)- Published
- 2020
- Full Text
- View/download PDF
42. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.
- Author
-
Huang B, Chen W, Zhao T, Li Z, Jiang X, Ginex T, Vílchez D, Luque FJ, Kang D, Gao P, Zhang J, Tian Y, Daelemans D, De Clercq E, Pannecouque C, Zhan P, and Liu X
- Subjects
- Animals, Binding Sites, Cell Line, Tumor, Female, HIV Reverse Transcriptase chemistry, HIV Reverse Transcriptase genetics, HIV-1 drug effects, Humans, Male, Mice, Molecular Docking Simulation, Molecular Dynamics Simulation, Molecular Structure, Mutation, Pyrimidines chemical synthesis, Pyrimidines toxicity, Reverse Transcriptase Inhibitors chemical synthesis, Reverse Transcriptase Inhibitors toxicity, Solubility, Structure-Activity Relationship, Pyrimidines pharmacology, Reverse Transcriptase Inhibitors pharmacology
- Abstract
Diarylpyrimidine derivatives (DAPYs) exhibit robust anti-HIV-1 potency, although they have been compromised by E138K variant and severe side-effects and been suffering from poor water solubility. In the present work, hydrophilic morpholine or methylsulfonyl and sulfamide-substituted piperazine/piperidines were introduced into the right wing of DAPYs targeting the solvent-exposed tolerant region I. The anti-HIV-1 activities of 11c (EC
50(WT) = 0.0035 μM, EC50(E138K) = 0.0075 μM) were the same as and 2-fold better than that of the lead etravirine against the wild-type and E138K mutant HIV-1, respectively, with a relative low cytotoxicity (CC50 ≥ 173 μM). Further test showed a significant improvement in the water solubility of 11c. Besides, 11c displayed no significant inhibition on main cytochrome P450 enzymes and exhibited no acute/subacute toxicities at doses of 2000 mg·kg-1 /50 mg·kg-1 in mice. Taken together, we consider that 11c is a promising lead for further structural optimization.- Published
- 2019
- Full Text
- View/download PDF
43. Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.
- Author
-
Espargaró A, Ginex T, Vadell MD, Busquets MA, Estelrich J, Muñoz-Torrero D, Luque FJ, and Sabate R
- Subjects
- Aged, Amyloid beta-Protein Precursor, Apigenin chemistry, Benzaldehydes chemistry, Cinnamates chemistry, Depsides chemistry, Humans, In Vitro Techniques, Molecular Structure, Peptide Fragments chemistry, Quercetin chemistry, Rosmarinic Acid, Alzheimer Disease drug therapy, Amyloid beta-Peptides antagonists & inhibitors, Flavonoids chemistry, Phenols chemistry, Quercetin pharmacology
- Abstract
Alzheimer's disease (AD) is the main cause of dementia in people over 65 years. One of the major culprits in AD is the self-aggregation of amyloid-β peptide (Aβ), which has stimulated the search for small molecules able to inhibit Aβ aggregation. In this context, we recently reported a simple, but effective in vitro cell-based assay to evaluate the potential antiaggregation activity of putative Aβ aggregation inhibitors. In this work this assay was used together with docking and molecular dynamics simulations to analyze the anti-Aβ aggregation activity of several naturally occurring flavonoids and phenolic compounds. The results showed that rosmarinic acid, melatonin, and o-vanillin displayed zero or low inhibitory capacity, curcumin was found to have an intermediate inhibitory potency, and apigenin and quercetin showed potent antiaggregation activity. Finally, the suitability of the combined in vitro cell-based/in silico approach to distinguish between active and inactive compounds was further assessed for an additional set of flavonols and dihydroflavonols.
- Published
- 2017
- Full Text
- View/download PDF
44. Preliminary hazard evaluation of androgen receptor-mediated endocrine-disrupting effects of thioxanthone metabolites through structure-based molecular docking.
- Author
-
Ginex T, Dall'Asta C, and Cozzini P
- Subjects
- Animals, Food Contamination, Humans, Molecular Docking Simulation, Rats, Thioxanthenes metabolism, Endocrine Disruptors metabolism, Receptors, Androgen metabolism, Xanthones metabolism
- Abstract
Foodstuff could be a vector for naturally occurring and/or unwanted dangerous substances that can act either as they are or after their bioactivation. The scientific community agrees that the metabolic activity of chemicals should be taken into account for proper risk assessment. Unfortunately, the in vitro evaluation of a metabolic panel and analytical/biochemical detection in food-safety assessment are very expensive and challenging because of the abundance of data to analyze. In this context, properly validated computational protocols could be a useful tool for making metabolic and binding/activity predictions. This strategy has been applied to thioxanthone photoinitiators (TX), identified as food contaminants, especially in infant formulas, as reported by the European Food Safety Authority in 2005. Their lipophilicity suggests rapid hepatic metabolism, but the currently available data only concern 2-ITX. We have predicted phase I metabolites for the TX class of compounds and defined their binding affinity for the AR ligand-binding pocket using a local model based on available information about metabolism and AR activity. Some metabolites should undergo further in vitro or/and in vivo toxicological evaluations because they have proved to be suitable as ligands for AR.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.